Univariable analysis for overall survival
| Covariate . | n (%) . | 100-d Death % (95%CI) . | HR (95%) . | P-value . |
|---|---|---|---|---|
| Age | ||||
| <65 y | 451 (53) | 13 (10-17) | 1.00 | |
| 65+ y | 394 (47) | 35 (29-41) | 3.34 (2.38-4.70) | <.001 |
| Gender | ||||
| F | 349 (41) | 16 (12-22) | 1.00 | |
| M | 496 (59) | 28 (23-33) | 1.60 (1.15-2.23) | .006 |
| Hb, g/dL | ||||
| 12+ | 446 (59) | 17 (13-22) | 1.00 | |
| <12 | 314 (41) | 34 (27-41) | 1.89 (1.38-2.59) | <.001 |
| ALC | ||||
| >650 | 523 (79) | 20 (16-25) | 1.00 | |
| ≤650 | 139 (21) | 38 (29-48) | 2.28 (1.60-3.25) | <.001 |
| NLR (ANC/ALC ratio) | ||||
| ≤3.5 | 434 (66) | 17 (13-22) | 1.00 | |
| >3.5 | 221 (34) | 36 (29-45) | 2.09 (1.49-2.94) | <.001 |
| Platelets | ||||
| 100+ | 551 (73) | 20 (16-25) | 1.00 | |
| <100 | 200 (27) | 32 (25-41) | 1.52 (1.09-2.12) | .014 |
| Charlson Index | ||||
| ≤6 | 643 (80) | 18 (15-23) | 1.00 | |
| >6 | 162 (20) | 40 (32-50) | 2.63 (1.90-3.64) | <.001 |
| Smoke | ||||
| Never | 424 (70) | 19 (15-25) | 1.00 | |
| Former | 127 (21) | 42 (32-54) | 2.16 (1.47-3.18) | <.001 |
| Current | 52 (9) | 30 (18-46) | 1.71 (0.94-3.09) | .077 |
| Never | 424 (70) | 19 (15-25) | 1.00 | |
| Smoke former/current | 179 (30) | 38 (30-48) | 2.04 (1.43-2.91) | <.001 |
| Lymphoma treatment | ||||
| Never had | 357 (43) | 18 (14-24) | 1.00 | |
| Yes, > 6 mo | 200 (24) | 29 (22-38) | 1.67 (1.11-2.50) | .012 |
| Yes, ≤ 6 mo | 274 (33) | 25 (20-33) | 1.67 (1.16-2.41) | .006 |
| Active vs not active | 1.00 (0.68-1.47) | .996 | ||
| Histology | ||||
| LBCL | 300 (36) | 30 (24-37) | 1.00 | |
| cHL | 114 (14) | 6 (3-14) | 0.30 (0.15-0.60) | .001 |
| i-NHL | 324 (39) | 21 (16-27) | 0.70 (0.50-0.99) | .049 |
| MCL | 59 (7) | 31 (17-52) | 0.97 (0.55-1.73) | .928 |
| T-cell | 43 (5) | 28 (16-46) | 1.29 (0.72-2.33) | .393 |
| i-NHL/HL | 438 (52) | 17 (13-22) | 1.00 | |
| LBCL/MCL/T | 402 (48) | 30 (24-36) | 1.73 (1.27-2.37) | .001 |
| Time, lymphoma to COVID-19 | ||||
| <3 mo | 135 (16) | 31 (23-42) | 1.00 | |
| 3-12 mo | 184 (22) | 26 (19-35) | 0.85 (0.54-1.34) | .486 |
| 12-24 mo | 132 (16) | 22 (15-31) | 0.71 (0.42-1.19) | .192 |
| 24-36 mo | 72 (9) | 19 (10-33) | 0.50 (0.24-1.00) | .050 |
| 36-48 mo | 58 (7) | 16 (7-34) | 0.45 (0.19-1.07) | .071 |
| >48 mo | 257 (31) | 25 (21-29) | 0.67 (0.43-1.04) | .077 |
| ≥12 mo | 519 (62) | 20 (16-25) | 1.00 | |
| <12 mo | 319 (38) | 28 (23-35) | 1.44 (1.06-1.96) | .020 |
| COVID-19 severity | ||||
| Mild | 500 (63) | 9 (6-13) | 1.00 | |
| Severe | 227 (29) | 38 (31-46) | 4.67 (3.16-6.90) | <.001 |
| Critical | 67 (8) | 75 (61-87) | 12.1 (7.82-18.6) | <.001 |
| Hospital admission | ||||
| No | 382 (45) | 5 (2-10) | 1.00 | |
| Yes | 463 (55) | 37 (32-43) | 8.82 (5.18-15.0) | <.001 |
| Lymphoma status at COVID-19 | ||||
| CR | 368 (46) | 16 (11-21) | 1.00 | |
| PR | 135 (17) | 22 (19-31) | 1.96 (1.24-3.10) | .004 |
| SD | 98 (12) | 26 (17-39) | 1.92 (1.15-3.20) | .013 |
| PD | 119 (15) | 41 (30-53) | 3.37 (2.21-5.14) | <.001 |
| W&W | 81 (10) | 22 (13-35) | 1.52 (0.85-2.73) | .162 |
| CR/W&W | 449 (56) | 17 (13-22) | 1.00 | |
| PR/SD | 233 (29) | 23 (18-30) | 1.77 (1.22-2.57) | .003 |
| PD | 119 (15) | 41 (30-53) | 3.08 (2.07-4.58) | <.001 |
| Covariate . | n (%) . | 100-d Death % (95%CI) . | HR (95%) . | P-value . |
|---|---|---|---|---|
| Age | ||||
| <65 y | 451 (53) | 13 (10-17) | 1.00 | |
| 65+ y | 394 (47) | 35 (29-41) | 3.34 (2.38-4.70) | <.001 |
| Gender | ||||
| F | 349 (41) | 16 (12-22) | 1.00 | |
| M | 496 (59) | 28 (23-33) | 1.60 (1.15-2.23) | .006 |
| Hb, g/dL | ||||
| 12+ | 446 (59) | 17 (13-22) | 1.00 | |
| <12 | 314 (41) | 34 (27-41) | 1.89 (1.38-2.59) | <.001 |
| ALC | ||||
| >650 | 523 (79) | 20 (16-25) | 1.00 | |
| ≤650 | 139 (21) | 38 (29-48) | 2.28 (1.60-3.25) | <.001 |
| NLR (ANC/ALC ratio) | ||||
| ≤3.5 | 434 (66) | 17 (13-22) | 1.00 | |
| >3.5 | 221 (34) | 36 (29-45) | 2.09 (1.49-2.94) | <.001 |
| Platelets | ||||
| 100+ | 551 (73) | 20 (16-25) | 1.00 | |
| <100 | 200 (27) | 32 (25-41) | 1.52 (1.09-2.12) | .014 |
| Charlson Index | ||||
| ≤6 | 643 (80) | 18 (15-23) | 1.00 | |
| >6 | 162 (20) | 40 (32-50) | 2.63 (1.90-3.64) | <.001 |
| Smoke | ||||
| Never | 424 (70) | 19 (15-25) | 1.00 | |
| Former | 127 (21) | 42 (32-54) | 2.16 (1.47-3.18) | <.001 |
| Current | 52 (9) | 30 (18-46) | 1.71 (0.94-3.09) | .077 |
| Never | 424 (70) | 19 (15-25) | 1.00 | |
| Smoke former/current | 179 (30) | 38 (30-48) | 2.04 (1.43-2.91) | <.001 |
| Lymphoma treatment | ||||
| Never had | 357 (43) | 18 (14-24) | 1.00 | |
| Yes, > 6 mo | 200 (24) | 29 (22-38) | 1.67 (1.11-2.50) | .012 |
| Yes, ≤ 6 mo | 274 (33) | 25 (20-33) | 1.67 (1.16-2.41) | .006 |
| Active vs not active | 1.00 (0.68-1.47) | .996 | ||
| Histology | ||||
| LBCL | 300 (36) | 30 (24-37) | 1.00 | |
| cHL | 114 (14) | 6 (3-14) | 0.30 (0.15-0.60) | .001 |
| i-NHL | 324 (39) | 21 (16-27) | 0.70 (0.50-0.99) | .049 |
| MCL | 59 (7) | 31 (17-52) | 0.97 (0.55-1.73) | .928 |
| T-cell | 43 (5) | 28 (16-46) | 1.29 (0.72-2.33) | .393 |
| i-NHL/HL | 438 (52) | 17 (13-22) | 1.00 | |
| LBCL/MCL/T | 402 (48) | 30 (24-36) | 1.73 (1.27-2.37) | .001 |
| Time, lymphoma to COVID-19 | ||||
| <3 mo | 135 (16) | 31 (23-42) | 1.00 | |
| 3-12 mo | 184 (22) | 26 (19-35) | 0.85 (0.54-1.34) | .486 |
| 12-24 mo | 132 (16) | 22 (15-31) | 0.71 (0.42-1.19) | .192 |
| 24-36 mo | 72 (9) | 19 (10-33) | 0.50 (0.24-1.00) | .050 |
| 36-48 mo | 58 (7) | 16 (7-34) | 0.45 (0.19-1.07) | .071 |
| >48 mo | 257 (31) | 25 (21-29) | 0.67 (0.43-1.04) | .077 |
| ≥12 mo | 519 (62) | 20 (16-25) | 1.00 | |
| <12 mo | 319 (38) | 28 (23-35) | 1.44 (1.06-1.96) | .020 |
| COVID-19 severity | ||||
| Mild | 500 (63) | 9 (6-13) | 1.00 | |
| Severe | 227 (29) | 38 (31-46) | 4.67 (3.16-6.90) | <.001 |
| Critical | 67 (8) | 75 (61-87) | 12.1 (7.82-18.6) | <.001 |
| Hospital admission | ||||
| No | 382 (45) | 5 (2-10) | 1.00 | |
| Yes | 463 (55) | 37 (32-43) | 8.82 (5.18-15.0) | <.001 |
| Lymphoma status at COVID-19 | ||||
| CR | 368 (46) | 16 (11-21) | 1.00 | |
| PR | 135 (17) | 22 (19-31) | 1.96 (1.24-3.10) | .004 |
| SD | 98 (12) | 26 (17-39) | 1.92 (1.15-3.20) | .013 |
| PD | 119 (15) | 41 (30-53) | 3.37 (2.21-5.14) | <.001 |
| W&W | 81 (10) | 22 (13-35) | 1.52 (0.85-2.73) | .162 |
| CR/W&W | 449 (56) | 17 (13-22) | 1.00 | |
| PR/SD | 233 (29) | 23 (18-30) | 1.77 (1.22-2.57) | .003 |
| PD | 119 (15) | 41 (30-53) | 3.08 (2.07-4.58) | <.001 |
OS evaluable on 845 patients (99%).